Figure 2.

Deletion of IGF2BP1 sensitizes mice to DSS colitis. A, survival curve for chronic DSS treatment showing significant loss of mice in the Villin-CreER^T2-Igf2bp1^fl/fl group. Age-matched (8–10-week) male and female Villin-CreER^T2-Igf2bp1^fl/fl (n = 8) and Igf2bp1^fl/fl (n = 8) mice were treated with 2% DSS in drinking water for 5 days followed by two additional cycles of 2% DSS with a 10–14-day interval between cycles. Mice were sacrificed on the 45th day of the experiment. B, percentage weight profile of mice during the experiment for chronic DSS treatment. C, DAI score plotted against time for chronic DSS treatment. D, representative pictures of colon and colon length comparison shown in the top. Scale bar, 25 mm. The lengths of age-matched female (14-16-week) Villin-CreER^T2-Igf2bp1^fl/fl (n = 3) and Igf2bp1^fl/fl (n = 3) mouse colons are quantified in the bottom panel. The data are mean ± S.D. (error bars). E, H&E-stained sections of colon from chronic DSS-treated Villin-CreER^T2-Igf2bp1^fl/f mice showing severe loss of colonic surface epithelium and crypts when compared with control mice. Scale bar, 50 μm. F, histomorphological scores were plotted for H&E-stained colon sections from the chronic DSS experiment. Colon sections were scored by a pathologist who was blinded for sample identity. *, p < 0.05; **, p < 0.01; ***, p < 0.001.